NCT05549531View on ClinicalTrials.gov

A Study to Investigate the Effect of Itraconazole on the Way the Body Absorbs, Distributes, and Gets Rid of ACT-1004-1239 Given as a Single Dose of 10 mg to Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

October 1, 2022

Primary Completion Date

October 20, 2022

Study Completion Date

October 20, 2022

Conditions
Healthy
Interventions
DRUG

ACT-1004-1239 (10 mg)

ACT-1004-1239 will be administered as 1 capsule of 10 mg strength to be taken under fed conditions.

DRUG

Itraconazole (200 mg, o.d.)

Itraconazole 200 mg will be administered as capsules (2 x 100 mg capsule) to be taken under fed conditions.

Trial Locations (1)

4250-449

BlueClinical Phase 1, Porto

Sponsors
All Listed Sponsors
lead

Idorsia Pharmaceuticals Ltd.

INDUSTRY

NCT05549531 - A Study to Investigate the Effect of Itraconazole on the Way the Body Absorbs, Distributes, and Gets Rid of ACT-1004-1239 Given as a Single Dose of 10 mg to Healthy Male Subjects | Biotech Hunter | Biotech Hunter